Abivax’s ulcerative colitis drug meets primary goals in Phase 3 trials; shares jump 400%

Published 23/07/2025, 12:22
© Reuters.

Investing.com -- Abivax shares rose over 400% in Paris on Wednesday after the French biotech company announced that its lead drug candidate obefazimod achieved primary endpoints in two Phase 3 clinical trials for ulcerative colitis.

According to topline data from the ABTECT-1 (Study 105) and ABTECT-2 (Study 106) trials, obefazimod administered at a 50 mg once-daily dose demonstrated statistically significant clinical remission at Week 8, meeting the primary endpoint in both studies.

The global trials evaluated oral obefazimod at 25 mg or 50 mg once-daily doses in more than 1,200 adults with moderately to severely active ulcerative colitis who had failed to respond, inadequately responded, or become intolerant to conventional and/or advanced therapies.

The Paris-based company reported that all key secondary endpoints were also met with the 50 mg once-daily dose of obefazimod in both studies.

On the safety front, Abivax noted that both doses of the experimental therapy were well tolerated among patients, with no new safety signals identified.

The company plans to file a New Drug Application (NDA) with the FDA in the second half of 2026, pending positive results from a 44-week maintenance trial. Topline data from this maintenance study is expected in the second quarter of 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.